Abraham Ishaaya, MD
Pulmonary Disease · Los Angeles, CANPI 1912959925
Payments from drug & device makers
Across 949 payments — averaging $43.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$19K
- AstraZeneca$3K
- Harmony Biosciences LLC$2K
- Jazz Pharmaceuticals Inc.$1K
- Amgen$1K
- Regeneron Healthcare Solutions, Inc.$1K
- plus $14K from 54 others
What the payments were for
- Consulting fees$850%
- Speaking & faculty fees$16,02239%
- Travel & lodging$2,0505%
- Food & beverage$21,59853%
- Education$6121%
- Gifts$6492%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$22,320
- FASENRA$1,076
- The Vest System 205 Acute Care$875
- The Vest System Model 105 Home Care$875
- The MetaNeb System$875
- The Monarch Airway Clearance System$875
- Volara System$875
- BREZTRI$782
- BioFire FilmArray RP EZ Kit (RFIT-ASY-0120)$649
- FARXIGA$572
- TEZSPIRE$514
- AIRSUPRA$421
- UPTRAVI$254
- OPSUMIT$254
- SYMBICORT$187
- Inspire$184
- CHARTIS CATHETER$151
- ZEPHYR DELIVERY CATHETER$151
- ZEPHYR ENDOBRONCHIAL VALVE$151
- PULMONX CHARTIS TABLET CONSOLE$151
How this compares
$41,015 in reported general payments places this provider in the 85th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TezspireTezepelumab-Ekko | 84 | $346,520 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 446 | $301,670 |
| OpsumitMacitentan | 20 | $245,011 |
| XolairOmalizumab | 81 | $227,773 |
| Dupixent PenDupilumab | 53 | $193,838 |
| OzempicSemaglutide | 154 | $149,469 |
| EliquisApixaban | 309 | $142,268 |
| MounjaroTirzepatide | 113 | $130,499 |
| EsbrietPirfenidone | 12 | $117,230 |
| Diclofenac Potassium | 54 | $115,228 |
| Dupixent SyringeDupilumab | 30 | $112,021 |
| SantylCollagenase Clostridium Hist. | 57 | $104,939 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 159 | $99,638 |
| JanuviaSitagliptin Phosphate | 147 | $96,401 |
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 86 | $96,394 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire, Breztri Aerosphere, Farxiga, Fasenra, Symbicort | $3,329 | $611,962478 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Nucala | $729 | $462,127680 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $460 | $245,01120 claims |
| Novo NordiskOzempic, Rybelsus | $358 | $182,442184 claims |
| Lilly USA, LLCMounjaro, Trulicity | $431 | $159,879145 claims |
| PfizerEliquis | $197 | $142,268309 claims |
| Genentech USA, Inc.Esbriet | $390 | $117,23012 claims |
| MerckJanuvia, Janumet Xr | $331 | $116,315172 claims |
| Boehringer IngelheimSpiriva Respimat, Jardiance | $1,033 | $81,236140 claims |
| Johnson & JohnsonProcrit | $33 | $70,75666 claims |
| AmgenEpogen | $1,060 | $58,280111 claims |
| AbbVieLinzess | $201 | $55,15294 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Los Angeles
- Toby MaherLos Angeles$27.6M
- Andrew WachtelLos Angeles$5.9M
- Michael RothLos Angeles$4.5M
- Rajan SaggarLos Angeles$3.3M
- Stephen Samuel WeigtLos Angeles$2.1M
- Robert WolfeLos Angeles$1.9M
- Igor BarjaktarevicLos Angeles$1.9M
- Shelley ShapiroLos Angeles$1M
- Victor TapsonLos Angeles$931K
- John BelperioLos Angeles$905K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.